François Karlien, Wissing Karl Martin, Jacobs Rita, Boone Dries, Jacobs Kristine, Tielemans Christian
Department of Nephrology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090 Jette, Belgium.
BMC Nephrol. 2014 Jul 3;15:104. doi: 10.1186/1471-2369-15-104.
Since October 2010, the combination of a heparin-grafted polyacrilonitrile (AN69ST) membrane with a 0.80 mmol/L citric acid-containing dialysate is routinely used in our centre for intermittent haemodialysis, without systemic anticoagulation, in critically ill patients with increased bleeding risk. The primary outcome of this retrospective cohort study was to assess the development of circuit clotting during these dialysis procedures. Secondly, we assessed the impact of clotting on treatment duration, the incidence rate of coagulation-induced retransfusion failure and the association of patient and dialysis characteristics with the occurrence of clotting.
Dialysis and patient data on consecutive intermittent haemodialysis procedures, performed at the Intensive Care Unit of Universitair Ziekenhuis Brussel between October 2010 and March 2012, were retrospectively reviewed. We used descriptive statistics as well as a random effects logit model with patient identity as a panel variable to assess associations.
Of a total of 309 treatments combining a heparin-grafted AN69ST membrane and a 0.8 mmol/L citric acid-enriched dialysate in 94 patients, circuit clotting was reported in 17.5% (95% CI 13.2% to 21.7%; N = 54), and in 19% (95% CI 13.6% to 24.4%; N = 40) of sessions with prescribed treatment time ≥ 4 hours (N = 210). Clotting shortened treatment time in 15.2% (95% CI 11.4% to 19.7%; N = 47) of sessions by a median of 55 (IQR 20 to 80) minutes. Complete clotting of the circuit with inability for retransfusion occurred in 4.2% (95% CI 2.2% to 7.0%; N = 13) of sessions. Circuit coagulation was not associated with APACHE II score, patient age, gender, number of treatments, type of vascular access or ultrafiltration rate.
Intermittent haemodialysis without systemic anticoagulation combining a heparin-grafted AN69ST dialyzer with a citrate-enriched dialysate favourably compares as to clotting complications with the published outcomes of anticoagulation-free intermittent haemodialysis strategies using saline flushes, heparin-coated dialyzer in combination with regular dialysate or regional citrate anticoagulation with calcium supplemented dialysate. The incidence of circuit clotting in our cohort appears to be higher than previously reported for regional citrate anticoagulation with a calcium-free dialysate.
自2010年10月起,我们中心常规使用肝素化聚丙烯腈(AN69ST)膜与含0.80 mmol/L柠檬酸的透析液联合用于重症出血风险增加的患者进行间歇性血液透析,无需全身抗凝。这项回顾性队列研究的主要结局是评估这些透析过程中体外循环凝血的发生情况。其次,我们评估了凝血对治疗时长、凝血导致的再次输血失败发生率的影响,以及患者和透析特征与凝血发生之间的关联。
回顾性分析2010年10月至2012年3月在布鲁塞尔大学医院重症监护病房进行的连续间歇性血液透析程序的透析和患者数据。我们使用描述性统计以及以患者身份作为面板变量的随机效应logit模型来评估关联。
在94例患者中,共进行了309次肝素化AN69ST膜与0.8 mmol/L富柠檬酸透析液联合的治疗,其中17.5%(95%CI 13.2%至21.7%;N = 54)报告发生体外循环凝血,在规定治疗时间≥4小时的透析疗程中,这一比例为19%(95%CI 13.6%至24.4%;N = 40)(N = 210)。在15.2%(95%CI 11.4%至19.7%;N = 47)的透析疗程中,凝血使治疗时间缩短,中位数为55(IQR 20至80)分钟。4.2%(95%CI 2.2%至7.0%;N = 13)的透析疗程出现体外循环完全凝血且无法再次输血。体外循环凝血与急性生理与慢性健康状况评分系统(APACHE II)评分、患者年龄、性别、治疗次数、血管通路类型或超滤率无关。
与已发表的使用盐水冲洗、肝素涂层透析器与常规透析液联合或用含钙透析液进行局部枸橼酸盐抗凝的无抗凝间歇性血液透析策略的结果相比,肝素化AN69ST透析器与富枸橼酸盐透析液联合进行无全身抗凝的间歇性血液透析在凝血并发症方面具有优势。我们队列中体外循环凝血的发生率似乎高于先前报道的使用无钙透析液进行局部枸橼酸盐抗凝的发生率。